Introduction OrsoBio is a clinical-stage biopharmaceutical company that focuses on developing therapies for patients with severe metabolic disorders, including diabetes, severe dyslipidemia, lipodystrophies, and more. The company is dedicated to restoring energy homeostasis in these patients by targeting pathways related to energy balance. By addressing the root cause of these disorders, OrsoBio aims to revolutionize their treatment. |
Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 6 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Enzyme | 1 |
Target |
Mechanism LXR inverse agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACC2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Mitochondrial oxidative phosphorylation uncouplers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date12 Aug 2024 |
Sponsor / Collaborator |
Start Date22 Apr 2023 |
Sponsor / Collaborator |
Start Date08 Mar 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TLC-2716 ( LXR ) | Metabolic dysfunction-associated steatotic liver disease More | Phase 2 |
S-723595 ( ACC2 ) | Insulin Resistance More | Phase 2 |
TLC-6740 | Obesity More | Phase 1 |
TLC-065 ( ACMSD ) | Liver Diseases More | Preclinical |
TLC-1235 | Lipodystrophy More | Preclinical |